Product Description
Anti-CD98 complete human antibody (Sourced from: https://www.kyowakirin.com/media_center/news_releases/2012/pdf/e20120727_01.pdf)
Mechanisms of Action: LAT1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kyowa Hakko Kirin
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01516645 |
KHK2898-001 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2015-05-01 |
2019-07-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|